BioWorld Asia

May 12, 2004

Arpida Raises CHF51.3M, Plans To Move Iclaprim Into Phase III

Arpida Ltd. raised CHF51.3 million (US$39.4 million) in a Series C funding round, bringing its total funding to date to CHF105 million. (BioWorld International) Read More

Faust Pharmaceuticals Closes EUR16M Second-Round Financing

Molecular Switch That Triggers Apoptosis Delivers Drug Target

Eirx Out-Licenses Apoptosis Targets To OSI In $18.8M Deal

Lectus Gets Investment From Takeda For PFD Protein Work

Report: 25 Recommendations For EU Strategies On Genetic Testing

Immatics Raises EUR8.5M In First Round Of Financing

Advanced Biotherapy Cross-Licenses IP With Innogenetics

Biota Holdings Suing GSK Over Support For Flu Drug

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Voyager’s gene therapy reduces tau levels in AD models

BioWorld Science

At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...

Illustration of T cells attacking cancer

GABA signaling linked to immune resistance in some tumors

BioWorld

Certain cancers that contain organized clusters of immune cells known as tertiary lymphoid structures (TLS) do not respond to treatment as well as expected. Even...